---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-166543"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2023-06-14T23:59:59+00:00"
generated_at: "2026-06-14T01:21:15.516656+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics appoints Sath Shukla as CEO, Mahadevia becomes Chairman

## Summary
- CEO Ankit Mahadevia steps down effective Aug 1, 2023; becomes Chairman of the Board.
- CFO Satyavrat 'Sath' Shukla appointed CEO and President, also joins Board.
- Stephen DiPalma appointed Interim CFO, effective Aug 1, 2023.
- Chairman Milind Deshpande steps down but remains director; Patrick Vink named Lead Independent Director.
- Mahadevia to receive $54k/month consulting fee through Jan 2024, then $310/hour through July 2025.

## SEC filing metadata
- accession: 0001193125-23-166543
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2023-06-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/0001193125-23-166543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/d509385d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-166543
- JSON: https://secwatch.observer/filing/0001193125-23-166543.json
- Plain text: https://secwatch.observer/filing/0001193125-23-166543.txt

## Key facts
- Executive change
  Ankit Mahadevia departed as Chief Executive Officer and President at Spero Therapeutics, Inc..
  - Action: stepped down
  - Role: Chief Executive Officer and President
  source text: Ankit Mahadevia, M.D., the Company’s Chief Executive Officer and President, determined to step down from that role, effective as of August 1, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/0001193125-23-166543-index.htm
- Executive change
  Satyavrat Shukla was appointed as Chief Executive Officer and President at Spero Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer and President
  source text: Satyavrat Shukla, the Company’s current Chief Financial Officer and Treasurer, was appointed by the Board to serve as Chief Executive Officer and President of the Company and as a member of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/0001193125-23-166543-index.htm
- Executive change
  Stephen J. DiPalma was appointed as Interim Chief Financial Officer and Treasurer at Spero Therapeutics, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer and Treasurer
  source text: Stephen J. DiPalma to be the Company’s Interim Chief Financial Officer and Treasurer to succeed Mr. Shukla
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/0001193125-23-166543-index.htm
- Executive change
  Ankit Mahadevia was appointed as Chairman of the Board at Spero Therapeutics, Inc..
  - Action: assume
  - Role: Chairman of the Board
  source text: Dr. Mahadevia will serve as a consultant to the Company and will continue to serve as a member of the Company’s Board of Directors (the “Board”) and will assume the role of Chairman of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312523166543/0001193125-23-166543-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.